Zevra therapeutics reports corporate updates and second quarter 2023 financial results

Completed collaborative and productive pre-submission meeting with fda for arimoclomol nda in august 2023; filing expected in q4 2023
ZVRA Ratings Summary
ZVRA Quant Ranking